Drug Discovery & Development

Drug Discovery & Development reports on cover #Drug introductions, formulations, pipeline candidates, #ClinicalTrial trends & #DrugDevelopments related to #AI

[Drug Discovery & Development @DrugDiscoverDev]

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

[Drug Discovery & Development @DrugDiscoverDev]

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

[Drug Discovery & Development @DrugDiscoverDev]

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

[Drug Discovery & Development @DrugDiscoverDev]

From monoclonal antibodies to CAR T, oncology biosimilars face scientific, regulatory, and adoption challenges. Learn how sponsors can prepare:
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Beyond approvals, uptake of biosimilars depends on education, real-world data, and trusted communication with providers and patients.
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Physician buy-in is essential for oncology biosimilar adoption. Misconceptions about quality and trial rigor persist—here’s how to address them:
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

[Drug Discovery & Development @DrugDiscoverDev]

Single‑use pump innovation: integrated bypass systems bring built-in pressure relief and seamless recirculation—no external components needed. Discover how it's shaping biopharma design:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

As biosimilars for cell therapies like CAR T emerge, questions remain: can regulatory bodies accept similarity in inherently unique therapies?
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Add pressure resilience to your biopharma workflows. Integrated bypass in single‑use pumps ensures automatic recirculation and avoids process interruptions. Read more:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

Recruiting patients for oncology biosimilar trials is harder than it seems—especially when the originator drug is already approved and accessible.
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

The 2025 Pharma 50 Deep Dives report goes beyond the rankings, identifying high-momentum drugs, tracking major decliners, analyzing biosimilar-driven market erosion, and examining the regulatory pressures shaping 2025. Access the free report: https://t.co/ZmboWKgVoj

[Drug Discovery & Development @DrugDiscoverDev]

Looking to bypass pressure-related failures? Next-gen single-use pumps integrate bypass circuits that trigger under overpressure—boosting safety and uptime. Learn more:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

Elevate your single‑use pump design: integrated bypass provides automatic flow recirculation during back‑pressure events—improving lifespan and system resilience. Details here:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

Monoclonal antibody biosimilars are growing—but ensuring consistent quality remains difficult due to manufacturing sensitivity and variability.
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Biopharmaceutical systems demand both simplicity and safety. Integrated bypass in single‑use pumps delivers both—protecting systems while keeping setup lean. Read how:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

Patent expirations open doors for oncology biosimilars, but complex modalities like ADCs, BsAbs, and CAR T cell therapies raise the bar. Explore why:
https://t.co/ZM9ZU3KB2F

[Drug Discovery & Development @DrugDiscoverDev]

Single‑use pumps now offer adjustable bypass systems that preserve flow control and reduce back-pressure—without external valves or complex piping. Explore the benefits:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

When pressure spikes arise, integrated bypass technology acts fast—recirculating flow automatically, protecting costly process systems. Discover how:
https://t.co/S1i72yJjDi

[Drug Discovery & Development @DrugDiscoverDev]

Oncology biosimilars can dramatically lower cancer treatment costs—but developing them is far from simple. Learn what makes them uniquely challenging:
https://t.co/ZM9ZU3KB2F